Item 1A. Risk Factors
2K characters. Original on sec.gov ·
Item 1A. Risk Factors
As of the date of this filing, there have been no material changes in our risk factors from those disclosed in Part I, Item 1A, of our Annual Report on Form 10-K for the fiscal year ended August 26, 2023.
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds
Shares of common stock repurchased by the Company during the quarter ended February 10, 2024 were as follows:
Issuer Repurchases of Equity Securities
| | | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|
| | | | | Total Number of | Maximum Dollar | |||||
| | | | | | | | Shares Purchased as | | Value that May Yet | |
| | | Total Number | | Average | | Part of Publicly | | Be Purchased Under | ||
| | | of Shares | | Price Paid | | Announced Plans or | | the Plans or | ||
| Period | | Purchased | | per Share | | Programs | | Programs | ||
| | | | | | | | | | | |
| November 19, 2023 to December 16, 2023 | 44,583 | | $ | 2,671.88 | 44,583 | | $ | 213,932,074 | ||
| December 17, 2023 to January 13, 2024 | 18,386 | | 2,599.28 | 18,386 | | 2,166,141,722 | ||||
| January 14, 2024 to February 10, 2024 | 20,674 | | 2,752.23 | 20,674 | | 2,109,242,181 | ||||
| Total | 83,643 | | $ | $2,675.78 | 83,643 | | $ | 2,109,242,181 |
During 1998, we announced a program permitting us to repurchase a portion of our outstanding shares not to exceed a dollar maximum established by our Board of Directors. This program was most recently amended by the Board on December 20, 2023 to authorize the repurchase of an additional $2.0 billion of our common stock. This brings the cumulative share repurchase authorization to $37.7 billion. All of the above repurchases were part of this program.
Subsequent to February 10, 2024 and through March 8, 2024, we have repurchased 63.0 thousand shares of our common stock at an aggregate cost of $180.7 million.
Item 3. Defaults Upon Senior Securities
Not applicable.
Item 4. Mine Safety Disclosures
Not applicable.
Previous: Item 4. Controls and Procedures · Next: Item 5. Other Information